NuCana management attributes lower nine-month 2026 pretax loss to absence of derivative revaluation losses
NCNA•NuCana reported a nine-month net loss of £8.55 million through September 30, 2026, down from £26.87 million a year earlier, when results included £12.65 million in noncash derivative revaluation losses. Cash and cash equivalents fell to £18.3 million from £24.3 million at December 31, 2025.
1. Nine-month results
NuCana reported a nine-month net loss of £8.55 million through September 30, 2026, compared with £26.87 million a year earlier. The improvement reflected lower expenses; the prior-year results included £12.65 million in noncash derivative revaluation losses. Research and development expenses fell to £6.24 million, primarily reflecting a £4.2 million reduction in share-based payment expenses.
2. Quarterly loss and cash
Third-quarter net loss widened to £1.61 million from £281,000, reflecting the absence of prior-year insurance proceeds and ADR depositary contributions. Cash and cash equivalents declined to £18.3 million at September 30, 2026, from £24.3 million at December 31, 2025.
